Monday, March 27, 2023 3:16:49 PM
ILT, my take is that the chances of Amarin succeeding on the Appeal need to be analyzed in terms of range of outcomes rather than absolutes. The Stock Twits poster is speaking in terms of an absolute, meaning he is absolutely certain that the Appeal is frivolous and that Rule 36 is forthcoming.
His prediction is certainly within the range of outcomes, especially if Judges Dyk and Reyna preside yet again, but that outcome is far from an absolute certainty. As we discussed last week, Amarin has couple of inherent appellate advantages in this Appeal, namely that the Magistrate got it right, and the standard on a Motion to Dismiss strongly favors denying the Motion while allowing the case to proceed through discovery.
The Magistrate's favorable ruling provides a roadmap for that outcome. Further, appellate review on a Motion to Dismiss is "de novo" as compared to "abuse of discretion". This means that the CAFC Panel need not defer to Judge Andrews, and will engage in its own analysis as to whether the case should have been dismissed.
As to amending the Complaint, Judge Andrews provided Amarin with that opportunity, but Amarin has taken the position that they do not need to amend the Complaint because the facts as pled state a claim, and Judge Andrews got it wrong. So rather than amend, Amarin has chosen to stand on its pleading, and get to the appellate court as soon as they could.
His prediction is certainly within the range of outcomes, especially if Judges Dyk and Reyna preside yet again, but that outcome is far from an absolute certainty. As we discussed last week, Amarin has couple of inherent appellate advantages in this Appeal, namely that the Magistrate got it right, and the standard on a Motion to Dismiss strongly favors denying the Motion while allowing the case to proceed through discovery.
The Magistrate's favorable ruling provides a roadmap for that outcome. Further, appellate review on a Motion to Dismiss is "de novo" as compared to "abuse of discretion". This means that the CAFC Panel need not defer to Judge Andrews, and will engage in its own analysis as to whether the case should have been dismissed.
As to amending the Complaint, Judge Andrews provided Amarin with that opportunity, but Amarin has taken the position that they do not need to amend the Complaint because the facts as pled state a claim, and Judge Andrews got it wrong. So rather than amend, Amarin has chosen to stand on its pleading, and get to the appellate court as soon as they could.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
